Doer Biologics Initiates Phase 3 Trial of GLP-1/GCG/FGF21 Triple Agonist DR10624 for Severe Hypertriglyceridemia
Jun 12, 2026 07:45
CST Updated
10:40
Doer Biologics
Biological Drug Developer
Biological Drug Developer